Publications by authors named "J Torp"
Brightfield cell microscopy is a foundational tool in life sciences. The acquired images are prone to contain visual artifacts that hinder downstream analysis, and automatically removing them is therefore of great practical interest. Deep convolutional neural networks are state-of-the-art for image segmentation, but require pixel-level annotations, which are time-consuming to produce.
View Article and Find Full Text PDFArticle Synopsis
- The M muscarinic acetylcholine receptor is a special type of protein in our body that scientists study because it relates to problems like drug addiction and mental illnesses.
- Researchers are testing two special fluorescent compounds that glow under certain lights to see how well they stick to this receptor.
- They created new methods using living cells and computer programs to easily analyze how well different substances can bind to the receptor, helping in the search for new medicines.
Fluorine-18 displays almost ideal decay properties for positron emission tomography (PET) and allows for large scale production. As such, simplified methods to radiolabel peptides with fluorine-18 are highly warranted. Chelation of aluminium fluoride-18 toward specific peptides represents one method to achieve this.
View Article and Find Full Text PDFBackground: As the patents of originator biologics are expiring, biosimilar versions are becoming available for the treatment of inflammatory bowel disease (IBD). However, published switch studies of the first infliximab biosimilar, CT-P13, have delivered ambiguous results that could be interpreted as showing a trend towards inferior effectiveness in Crohn's disease (CD) compared with ulcerative colitis (UC). The aim of this study was to investigate the effectiveness and safety of switching IBD patients from treatment with Remicade to CT-P13.
View Article and Find Full Text PDFBackground: Real-life long-term data on infliximab treatment in ulcerative colitis are limited.
Aim: To study the long-term efficacy and safety of infliximab in chronic active ulcerative colitis and possible predictors of colectomy and response were also examined.
Methods: A retrospective multi-centre study of infliximab treatment in 250 patients with chronic active ulcerative colitis with inclusion criteria: age ≥18 years, ambulatory treated, steroid-dependent or intolerant and/or immunomodulator refractory or intolerant.